Profound Medical (PROF) Projected to Post Earnings on Thursday

Profound Medical (NASDAQ:PROF) is expected to release its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect Profound Medical to post earnings of ($0.28) per share and revenue of $10.5260 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:30 PM ET.

Profound Medical Price Performance

Shares of NASDAQ:PROF opened at $7.46 on Tuesday. The business’s fifty day moving average price is $7.46 and its two-hundred day moving average price is $6.29. Profound Medical has a fifty-two week low of $3.76 and a fifty-two week high of $8.95. The stock has a market capitalization of $270.75 million, a price-to-earnings ratio of -5.57 and a beta of 0.60.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its stake in Profound Medical by 56.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock valued at $147,000 after acquiring an additional 6,787 shares during the last quarter. Corsair Capital Management L.P. acquired a new stake in shares of Profound Medical in the 4th quarter valued at $208,000. Millennium Management LLC acquired a new stake in shares of Profound Medical in the 4th quarter valued at $211,000. Quadrature Capital Ltd bought a new position in shares of Profound Medical in the 4th quarter valued at $256,000. Finally, Hohimer Wealth Management LLC acquired a new position in shares of Profound Medical during the 4th quarter worth $394,000. 47.86% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on PROF. Wall Street Zen raised Profound Medical from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Lake Street Capital lifted their target price on Profound Medical from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Profound Medical in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Profound Medical has an average rating of “Hold” and an average target price of $12.00.

Profound Medical Company Profile

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.